Royalty Pharma Plc · NASDAQ:RPRX
Royalty Pharma — Investor Presentation (May 2024)
20 slides from Royalty Pharma's investor presentation, May 2024
Slide 1: Royalty Pharma
ROYALTY PHARMA
Slide 2: Vorasidenib Royalty Transaction
Vorasidenib Royalty Transaction May 2024
Slide 3: Forward Looking Statements
Forward Looking Statements This presentation has been prepared by Royalty Pharma plc (the “Company”), is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities. The information set forth herein does not purport to be complete or
Slide 4: Agenda
Agenda Highlights Pablo Legorreta Founder & Chief Executive Officer Vorasidenib transaction Marshall Urist EVP, Head of Research and Investments Cytokinetics transaction Chris Hite EVP, Vice Chairman Conclusion Pablo Legorreta Founder & Chief Executive Officer Pablo Legorreta Founder & Chief Executi
Slide 5: Key Highlights
Key Highlights Pablo Legorreta Founder & Chief Executive Officer
Slide 6: Vorasidenib – potentially transformative therapy for glioma
Vorasidenib – potentially transformative therapy for glioma 1 2 3 Significant unmet need Potentially transformative Blockbuster opportunity Vorasidenib would be the first targeted Vorasidenib showed an impressive Potential to be an important product for therapy for IDH-mutant glioma, a improvement i
Slide 7: Clear leader in large royalty transactions
Clear leader in large royalty transactions Royalty transactions ≥$500m Market share of deals ≥$500m ($ in millions) (by count) Lead product Acquiror Post-IPO Transaction size Trikafta(1) 3,352 Tysabri 2,850 Trelegy(2) 1,650 Tremfya(3) 1,575 Evrysdi 1,500 Keytruda Other 1,297 Leqvio Other 1,150 Xtand
Slide 8: Vorasidenib Transaction
Vorasidenib Transaction Marshall Urist, MD, PhD Executive Vice President Head of Research & Investments
Slide 9: Royalty transaction for Servier's vorasidenib
Royalty transaction for Servier’s vorasidenib • Acquired a royalty interest in Servier’s vorasidenib for low-grade glioma from Agios Pharmaceuticals 15% royalty on U.S. sales of ▪ $905m upfront payment on FDA approval vorasidenib by Servier(1) ▪ Entitled to 15% royalty on U.S. net sales up to $1 bil
Slide 10: Vorasidenib – expected to become standard of care for LGG
Vorasidenib – expected to become standard of care for LGG Typical glioma patient journey 1. 2. 3. 4. Brain tumor diagnosis Surgical resection or biopsy Sample pathology and grading Treatment current Grade 1 (benign) Radiation/chemo (potential remission, high toxicity) Biopsy only Partial Low grade g
Slide 11: Phase 3 results demonstrate practice-changing potential
Phase 3 results demonstrate practice-changing potential Progression-free survival(1) Receipt of next intervention(2) (Primary endpoint) (Key secondary endpoint) Probability of progression-free survival 1.0 1.0 Probability of being alive and not 0.9 0.9 Vorasidenib, median not reached receiving next
Slide 12: Vorasidenib has a differentiated safety profile
Vorasidenib has a differentiated safety profile Radiotherapy + PCV Vorasidenib (RTOG9802) • Vorasidenib was well-tolerated in Phase 3 INDIGO study 98% ▪ Most notable safety and tolerability signals were minor and manageable liver side effects • Radiation chemotherapy is current standard of care but
Slide 13: Vorasidenib – a potentially transformative therapy for LGG
Vorasidenib – a potentially transformative therapy for LGG Market dynamics in low-grade glioma RP survey indicates high physician excitement ✓ ~1,500 ~10,000 88% Broad uptake High unmet need Incident U.S. Prevalent U.S. Of physicians agree Broad uptake expected across with no approved patients patie
Slide 14: Cytokinetics Transaction
Cytokinetics Transaction Chris Hite Executive Vice President Vice Chairman
Slide 15: Repeat transactions highlight value of Royalty Pharma partnership
Repeat transactions highlight value of Royalty Pharma partnership vorasidenib, aficamten, omecamtiv, CK-586 , BCX10013 , BCX10013 $1.16bn total funding Up to $1.13bn total funding Up Upto to$2.15bn $325m total totalfunding funding Up to $325m total funding 2x 2020, 2024 3x 2017, 2022, 2024 2x 2020,
Slide 16: May 2024 transaction – strengthening Cytokinetics partnership
May 2024 transaction – strengthening Cytokinetics partnership • RP committed up to $1.13bn in total funding across three deals(1) • Aficamten is a potential best-in-class therapy for HCM Royalty Pharma provides incremental royalty and ▪ Entitled to 4.5% royalty up to $5bn and 1.0% royalty above $5bn
Slide 17: Conclusion
Conclusion Pablo Legorreta Founder & Chief Executive Officer
Slide 18: Announced transactions of ~$2.0 billion over the past three weeks
Announced transactions of ~$2.0 billion over the past three weeks Recently announced transactions Announcement date 5/28/2024 5/22/2024 5/9/2024 Transaction size $905 million Up to $575 million ~$525 million Marketer Servier Cytokinetics Sanofi omecamtiv Therapy vorasidenib aficamten CK-586 frexalim
Slide 19: Appendix
Appendix ROYALTY PHARMA
Slide 20: Detailed Cytokinetics partnership overview
Detailed Cytokinetics partnership overview Tranche Capital available Capital drawn(1) Key details Funding timing Other $ in USD millions • 4.5% up to $5.0bn * aficamten(2) -- -- $150 • Funded • 1.0% on over $5.0bn 1 -- $50 • Funded 4 $75 -- • Available until Q2’25 • 1.90x funded amount • 1.90x over